# Elevance Health Inc. (ELV) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $407.50, market value $88.4 billion.

## Valuation
- **P/E (trailing): 18.0×** (5-yr avg 16.6×, 3-yr avg 15.2×). Elevance Health Inc. trades at 18.0× trailing earnings, close to its own five-year average of 16.6×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.4×**. Each dollar of revenue is priced at 0.4×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 15.9×**. Enterprise value is 15.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 7.1%** (5-yr avg 5.8%). Free cash flow equals 7.1% of the market value, above its five-year average of 5.8%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 5.6%**. The inverse of the P/E: 5.6% of the price is earned each year.

## Profitability
- **Operating margin: 2.7%**. 2.7% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 2.8%**. 2.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.9%**. 12.9% on shareholders' equity is solid.
- **Return on invested capital: 6.5%**. Return on all capital, debt included, is 6.5%.
- **Return on assets: 4.1%**. Each dollar of assets produces 4.1% of profit.

## Growth
- **Revenue growth (1 yr): 12.5%** (3-yr 8.3%/yr, 5-yr 10.3%/yr). Revenue grew 12.5% over the last year, against 10.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -1.8%** (3-yr 1.3%/yr, 5-yr 7.0%/yr). Earnings per share fell 1.8%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -24.1%/yr**. Free cash flow has compounded at -24.1% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.73**. Debt is 0.73 times equity, moderate leverage.
- **Net debt / EBITDA: 3.2×**. It would take 3.2 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 3.02**. A Z-score of 3.02 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 1.69%** ($6.86 per share, trailing). Elevance Health Inc. yields 1.69%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 27%**. 27% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 15**. 15 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 12.5%/yr** (1-yr 4.9%). The dividend has compounded at 12.5% a year over five years, doubling roughly every 6 years at that pace.

## Analyst view
- **Analyst consensus: buy** (21 analysts). 21 analysts cover Elevance Health Inc.; the consensus is buy, with an average price target of $449.10 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 35.1%** (YTD 17.4%, 3-mo -1.5%). The shares are up 35.1% over twelve months including dividends.
- **From 52-week high: -6.6%** (48.3% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 0.33** (volatility 35%). Beta of 0.33 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ELV · Page: https://foliofundamentals.com/stocks/elv

Not investment advice.